Q-Line Biotech Ltd vs Torrent Pharmaceuticals Ltd

A side-by-side comparison of Q-Line Biotech Ltd (QLINE) and Torrent Pharmaceuticals Ltd (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

Q-Line Biotech Ltd and Torrent Pharmaceuticals Ltd are evenly matched on the numbers (77). The breakdown below shows where each one wins.

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

14.94
P/E ratio
78.86
2.65
P/B ratio
20.18
0.00%
Dividend yield
0.76%
₹34.24
EPS
₹63.92

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

25.90%
Return on equity
27.40%
22.00%
Return on capital
15.00%
29.00%
EBITDA margin
33.00%
16.37%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

23.18%
Revenue CAGR (3Y)
13.27%
20.51%
Profit CAGR (3Y)
19.75%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1,316 Cr
Market cap
₹1.84L Cr
₹342 Cr
Revenue
₹13,980 Cr
₹56 Cr
Net profit
₹2,138 Cr
0.75
Debt / equity
1.79
Q-Line Biotech Ltd
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%"]
  • ["Debtor days have increased from 92.7 to 134 days."]
Torrent Pharmaceuticals Ltd
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 19.2 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Q-Line Biotech Ltd full analysis Torrent Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.